Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimation of US Patients with Cancer who may Respond to Cytotoxic Chemotherapy

25 Jun 2020

Abstract excerpt

AIMS PATIENTS & METHODS: In this retrospective review, we sought to estimate the proportion of patients in the USA with advanced or metastatic cancer who are eligible for and may respond to recommended first-line cytotoxic chemotherapy based on National Comprehensive Cancer Network treatment guidelines. RESULTS: Among 609,640 patients, we estimate 479,823 (78.7%, 95% CI: 78.6-78.8%) may be eligible for cytotoxic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32983564
DOI: 10.2144/fsoa-2020-0024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimation of US Patients with Cancer who may Respond to Cytotoxic ChemotherapyPMID 32983564Read ↗

Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven OncologySemantic proximity Read ↗

Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunitiesSemantic proximity Read ↗

Whole-exome sequencing of 79 xenografts as a potential approach for the identification of genetic variants associated with sensitivity to cytotoxic anticancer drugs.Semantic proximity Read ↗

Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.Semantic proximity Read ↗

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020Semantic proximity Read ↗

Pharmacogenomic Characterization of US FDA-approved Cytotoxic DrugsSemantic proximity Read ↗

Why does cytotoxic chemotherapy cure only some cancers?Semantic proximity Read ↗

Assessment of anticancer drug utilization pattern and patients’ survival—A single center experience from Saudi ArabiaSemantic proximity Read ↗

Strategies to design clinical studies to identify predictive biomarkers in cancer research.Semantic proximity Read ↗

Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response RatesSemantic proximity Read ↗

Predicting response to cytotoxic chemotherapySemantic proximity Read ↗

Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.